UNH
UnitedHealth Group Incorporated
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+22/100
Last price
376.18
▼ 2.40 (0.64%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
378.10
Prev close
378.58
Day high
380.41
Day low
373.70
Volume
5.04M
Market cap
$337.78B
P/E (TTM)
24.34
52W range
255.97 – 461.62
Day trading desk
Gap from prior close
-0.13%
Prior close 378.58
VWAP
375.77
+0.11% from price
Relative volume
1.26×
Normal
Session range
2.73%
370.31 – 380.41
Position in range
58%
Mid range
ATR (14D)
7.54
2.01% of price
Prior day high
379.14
PDH
Prior day low
368.05
PDL
Bid / ask spread
—
Quote not published
Session volume
6.17M
Avg 4.89M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+0.37%
-1.6%
1M
-5.24%
-6.4%
3M
-11.58%
-16.1%
6M
+22.29%
+4.1%
YTD
+14.00%
-0.3%
1Y
+4.48%
-11.9%
3Y
-25.36%
-107.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on UNH open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+5.06K
Net buying
Buy transactions
53
7.53K shares
Sell transactions
3
2.47K shares
Net transactions
+56
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
2.23M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 1, 26 | GOTTLIEB SCOTT Director |
STOCK | 257 | $0 | Direct |
| Oct 1, 26 | BAKER CHARLES D Director |
STOCK | 257 | $0 | Direct |
| Oct 1, 26 | GARCIA PAUL REU Director |
STOCK | 258 | $0 | Direct |
| Oct 1, 26 | GIL KRISTEN Director |
STOCK | 240 | $0 | Direct |
| Oct 1, 26 | MCNABB FREDERICK WILLIAM III Director |
STOCK | 291 | $0 | Direct |
| Oct 1, 26 | MONTGOMERY RICE VALERIE C Director |
STOCK | 257 | $0 | Direct |
| Oct 1, 26 | NOSEWORTHY JOHN H Director |
STOCK | 240 | $0 | Direct |
| Oct 1, 26 | FLYNN TIMOTHY PATRICK Director |
STOCK | 262 | $0 | Direct |
| Sep 22, 26 | GOTTLIEB SCOTT Director |
STOCK | 5 | $0 | Direct |
| Sep 22, 26 | DEVEYDT WAYNE S Chief Financial Officer |
STOCK | 106 | $0 | Direct |
| Sep 22, 26 | HEMSLEY STEPHEN J Officer and Director |
STOCK | 50 | $0 | Direct |
| Sep 22, 26 | BAKER CHARLES D Director |
STOCK | 15 | $0 | Direct |
| Sep 22, 26 | MCSWEENEY ERIN L Officer |
STOCK | 53 | $0 | Direct |
| Sep 22, 26 | ZAETTA CHRISTOPHER R Officer |
STOCK | 66 | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CIANFROCCO HEATHER |
Officer | 22.44K | Stock Award(Grant) |
DEVEYDT WAYNE S |
Chief Financial Officer | 18.68K | Stock Award(Grant) |
FLYNN TIMOTHY PATRICK |
Director | 17.24K | Stock Award(Grant) |
HEMSLEY STEPHEN J |
Officer and Director | 1.06M | Stock Award(Grant) |
HOOPER MICHELE J. |
Director | 41.79K | Stock Award(Grant) |
NOEL TIMOTHY JOHN |
Officer | 17.73K | Stock Award(Grant) |
REX JOHN F |
President | 210.69K | Stock Award(Grant) |
ROOS THOMAS E |
Officer | 31.28K | Stock Award(Grant) |
WITTY ANDREW PHILIP |
Chief Executive Officer | 112.16K | Stock Award(Grant) |
ZAETTA CHRISTOPHER R |
Officer | 15.93K | Stock Award(Grant) |
Fundamentals
Market cap$337.78B
Enterprise value$387.14B
Revenue (TTM)$450.53B
Gross profit$88.86B
EBITDA$26.68B
Net income$14.12B
EPS (TTM)$15.46
Free cash flow$24.27B
Total cash$31.47B
Total debt$73.33B
Book value / share$108.78
Shares outstanding897.59M
Float895.02M
Short % of float1.64%
Dividend yield2.45%
Beta (5Y)0.62
Valuation & profitability ratios
Trailing P/E24.34
Forward P/E16.64
PEG ratio1.03
Price / sales—
Price / book3.46
EV / revenue0.86
EV / EBITDA14.51
Gross margin19.72%
Operating margin7.13%
Profit margin3.14%
Return on equity14.15%
Return on assets4.87%
Debt / equity69.21
Current ratio0.78
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $447.57B | $400.28B | $371.62B | $324.16B | +11.8% |
| Operating revenue | $447.57B | $400.28B | $371.62B | $324.16B | +11.8% |
| Cost of revenue | $364.65B | $310.88B | $280.66B | $244.54B | +17.3% |
| Gross profit | $82.92B | $89.40B | $90.96B | $79.62B | -7.3% |
| Total operating expense | $63.95B | $57.11B | $58.60B | $51.18B | +12.0% |
| Operating income | $18.96B | $32.29B | $32.36B | $28.43B | -41.3% |
| Net interest income | -$4.00B | -$3.91B | -$3.25B | -$2.09B | -2.5% |
| Pre-tax income | $14.70B | $20.07B | $29.11B | $26.34B | -26.8% |
| Tax provision | $1.89B | $4.83B | $5.97B | $5.70B | -60.9% |
| Net income | $12.06B | $14.40B | $22.38B | $20.12B | -16.3% |
| Net income to common | $12.06B | $14.40B | $22.38B | $20.12B | -16.3% |
| Basic EPS | 13.31 | 15.74 | 24.22 | 21.54 | -15.5% |
| Diluted EPS | 13.23 | 15.51 | 23.86 | 21.18 | -14.7% |
| EBIT | $18.70B | $23.98B | $32.36B | $28.43B | -22.0% |
| EBITDA | $23.06B | $28.08B | $36.33B | $31.84B | -17.9% |
| Basic shares | 905.84M | 915.00M | 924.00M | 934.00M | -1.0% |
| Diluted shares | 911.00M | 929.00M | 938.00M | 950.00M | -1.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $24.36B | $25.31B | $25.43B | $23.36B | -3.7% |
| Cash & short-term investments | $28.12B | $29.11B | $29.63B | $27.91B | -3.4% |
| Accounts receivable | $23.02B | $22.36B | $21.28B | $17.68B | +2.9% |
| Total current assets | $90.58B | $85.78B | $78.44B | $69.07B | +5.6% |
| Property, plant & equipment | $10.76B | $10.55B | $11.45B | $10.13B | +2.0% |
| Goodwill & intangibles | $130.97B | $130.00B | $118.93B | $107.75B | +0.7% |
| Total assets | $309.58B | $298.28B | $273.72B | $245.71B | +3.8% |
| Total current liabilities | $114.90B | $103.77B | $99.05B | $89.24B | +10.7% |
| Current debt | $6.07B | $4.54B | $4.27B | $3.11B | +33.5% |
| Long-term debt | $72.32B | $72.36B | $58.26B | $54.51B | -0.1% |
| Total debt | $78.39B | $76.90B | $62.54B | $57.62B | +1.9% |
| Total liabilities | $207.88B | $195.69B | $174.80B | $159.36B | +6.2% |
| Retained earnings | $95.60B | $96.04B | $95.77B | $86.16B | -0.5% |
| Shareholder equity | $94.11B | $92.66B | $88.76B | $77.77B | +1.6% |
| Working capital | -$24.32B | -$17.99B | -$20.62B | -$20.17B | -35.2% |
| Net tangible assets | -$36.86B | -$37.34B | -$30.17B | -$29.98B | +1.3% |
| Shares issued | 905.84M | 915.00M | 924.00M | 934.00M | -1.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $12.81B | $15.24B | $23.14B | $20.64B | -16.0% |
| Depreciation & amortisation | $4.36B | $4.10B | $3.97B | $3.40B | +6.4% |
| Stock-based compensation | $971.00M | $1.02B | $1.06B | $925.00M | -4.6% |
| Change in working capital | $2.28B | -$808.00M | $1.64B | $2.25B | +382.4% |
| Operating cash flow | $19.70B | $24.20B | $29.07B | $26.21B | -18.6% |
| Capital expenditure | -$3.62B | -$3.50B | -$3.39B | -$2.80B | -3.5% |
| Investing cash flow | -$8.69B | -$20.53B | -$15.57B | -$28.48B | +57.7% |
| Share buybacks | -$5.54B | -$9.00B | -$8.00B | -$7.00B | +38.4% |
| Dividends paid | -$7.92B | -$7.53B | -$6.76B | -$5.99B | -5.1% |
| Financing cash flow | -$11.64B | -$3.51B | -$11.53B | $4.23B | -231.5% |
| Free cash flow | $16.07B | $20.70B | $25.68B | $23.40B | -22.4% |
| End cash position | $24.36B | $25.31B | $25.43B | $23.36B | -3.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $112.03B | $111.72B | $113.22B | $113.16B | $111.62B | +0.3% |
| Operating revenue | $112.03B | $111.72B | $113.22B | $113.16B | $111.62B | +0.3% |
| Cost of revenue | $88.73B | $86.31B | $94.72B | $92.52B | $91.60B | +2.8% |
| Gross profit | $23.30B | $25.41B | $18.49B | $20.64B | $20.01B | -8.3% |
| Total operating expense | $15.31B | $16.42B | $18.11B | $16.32B | $14.86B | -6.8% |
| Operating income | $7.99B | $8.99B | $380.00M | $4.32B | $5.15B | -11.1% |
| Net interest income | -$962.00M | -$955.00M | -$974.00M | -$1.00B | -$1.03B | -0.7% |
| Pre-tax income | $6.97B | $7.96B | -$720.00M | $3.23B | $4.08B | -12.5% |
| Tax provision | $1.30B | $1.48B | -$938.00M | $686.00M | $510.00M | -12.4% |
| Net income | $5.48B | $6.28B | $10.00M | $2.35B | $3.41B | -12.7% |
| Net income to common | $5.48B | $6.28B | $10.00M | $2.35B | $3.41B | -12.7% |
| Basic EPS | 6.06 | 6.92 | 0.01 | 2.59 | 3.76 | -12.4% |
| Diluted EPS | 6.04 | 6.90 | 0.01 | 2.59 | 3.74 | -12.5% |
| EBIT | $7.93B | $8.92B | $254.00M | $4.23B | $5.11B | -11.1% |
| EBITDA | $8.97B | $9.95B | $1.37B | $5.33B | $6.19B | -9.8% |
| Basic shares | 902.00M | 907.68M | 905.84M | 905.67M | 905.00M | -0.6% |
| Diluted shares | 906.00M | 910.00M | 910.00M | 908.00M | 910.00M | -0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.59B | $28.00B | $24.36B | $27.21B | $28.60B | +2.1% |
| Cash & short-term investments | $31.47B | $31.23B | $28.12B | $30.61B | $32.02B | +0.8% |
| Accounts receivable | $21.57B | $26.59B | $23.02B | $22.67B | $24.14B | -18.9% |
| Total current assets | $86.86B | $91.13B | $90.58B | $95.07B | $93.70B | -4.7% |
| Property, plant & equipment | $10.76B | $10.67B | $10.76B | $11.10B | $10.92B | +0.9% |
| Goodwill & intangibles | $130.39B | $130.60B | $130.97B | $133.13B | $130.19B | -0.2% |
| Total assets | $309.73B | $312.64B | $309.58B | $315.27B | $308.57B | -0.9% |
| Total current liabilities | $111.82B | $114.12B | $114.90B | $115.53B | $110.78B | -2.0% |
| Current debt | $3.83B | $6.48B | $6.07B | $7.74B | $5.70B | -40.9% |
| Long-term debt | $69.50B | $71.44B | $72.32B | $72.40B | $73.50B | -2.7% |
| Total debt | $73.33B | $77.92B | $78.39B | $80.14B | $79.19B | -5.9% |
| Total liabilities | $203.78B | $207.32B | $207.88B | $209.46B | $203.79B | -1.7% |
| Retained earnings | $100.96B | $99.88B | $95.60B | $97.59B | $97.25B | +1.1% |
| Shareholder equity | $98.45B | $97.88B | $94.11B | $95.79B | $94.72B | +0.6% |
| Working capital | -$24.96B | -$23.00B | -$24.32B | -$20.46B | -$17.08B | -8.5% |
| Net tangible assets | -$31.95B | -$32.72B | -$36.86B | -$37.34B | -$35.46B | +2.4% |
| Shares issued | 905.00M | 907.68M | 905.84M | 905.67M | 905.00M | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $5.67B | $6.48B | $218.00M | $2.54B | $3.57B | -12.5% |
| Depreciation & amortisation | $1.04B | $1.03B | $1.12B | $1.10B | $1.08B | +1.1% |
| Stock-based compensation | $276.00M | $348.00M | $176.00M | $223.00M | $197.00M | -20.7% |
| Change in working capital | $4.07B | $746.00M | -$495.00M | $2.99B | $2.42B | +444.9% |
| Operating cash flow | $11.05B | $8.91B | $1.11B | $5.95B | $7.19B | +24.0% |
| Capital expenditure | -$799.00M | -$763.00M | -$948.00M | -$890.00M | -$886.00M | -4.7% |
| Investing cash flow | -$1.80B | -$2.45B | -$2.61B | -$4.56B | -$1.44B | +26.5% |
| Share buybacks | -$1.65B | $0 | $0 | $0 | -$2.54B | — |
| Dividends paid | -$2.09B | -$2.00B | -$2.00B | -$2.00B | -$2.00B | -4.1% |
| Financing cash flow | -$8.62B | -$2.99B | -$1.03B | -$2.77B | -$7.95B | -188.2% |
| Free cash flow | $10.25B | $8.15B | $160.00M | $5.05B | $6.30B | +25.8% |
| End cash position | $28.59B | $28.00B | $24.36B | $27.21B | $28.60B | +2.1% |
Options analytics
Put / call volume
1.06
Put-heavy session
Put / call open interest
1.87
Positioning, not flow
Max pain
375.00
-0.4% from spot
ATM implied vol
53.9%
Nearest strike to spot
Skew (10% OTM)
+12.6%
Puts bid over calls
Call volume
6.71K
Contracts, this expiry
Put volume
7.12K
Contracts, this expiry
Heaviest call OI
380.00
2.39K contracts
Heaviest put OI
370.00
9.72K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 4.92 | 6.38 | +29.8% |
| Mar 2026 | 6.60 | 7.23 | +9.5% |
| Dec 2025 | 2.11 | 2.11 | +0.2% |
| Sep 2025 | 2.81 | 2.92 | +4.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 4.15 | 23 | $111.49B | -1.5% |
| Next quarter | 2.10 | 23 | $111.28B | -1.7% |
| Current year | 19.87 | 25 | $447.09B | -0.1% |
| Next year | 22.61 | 26 | $460.09B | +2.9% |
Analyst targets & ownership
Mean target$481.72
High target$529.00
Low target$380.00
Implied upside28.06%
Analyst count25
ConsensusBUY
Strong buy / Buy7 / 15
Hold4
Sell / Strong sell0 / 0
Held by insiders0.25%
Held by institutions89.63%
Institutions holding4.34K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
373.47
+0.72% from price
SMA 20
376.63
-0.08% from price
SMA 50
392.07
-4.02% from price
SMA 100
400.00
-5.96% from price
SMA 200
356.80
+5.47% from price
EMA 12
375.11
+0.28% from price
EMA 26
380.63
-1.17% from price
EMA 50
387.31
-2.88% from price
RSI (14)
45.4
Neutral
MACD (12,26,9)
-5.53
Hist 0.97
ATR (14)
7.54
2.00% of price
Realised vol 30D
18.6%
Annualised
Bollinger upper
388.97
20, 2σ
Bollinger lower
364.28
20, 2σ
50 / 200 cross
Golden
392.07 vs 356.80
Trend bias
Above 200
+5.47%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.43
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
18.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-30.0%
Peak to trough
Max drawdown 5Y
-62.0%
Peak to trough
ATR 14
7.54
2.00% of price
Beta (reported)
0.62
5Y monthly, from filing
Short interest
Shares short
13.22M
Prior 15.46M
Change vs prior
-14.5%
Shorts covering
% of float
1.64%
Normal
% of shares out
1.47%
Against total outstanding
Days to cover
2.8
Liquid
Float
895.02M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 21, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jul 21, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jul 20, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 17, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jul 17, 26 | Keybanc | MAINTAINED | Overweight | Overweight |
| Jul 17, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Jul 17, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jul 17, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 17, 26 | UBS | MAINTAINED | Buy | Buy |
| Jul 16, 26 | Baird | UPGRADE | Underperform | Neutral |
| Jul 14, 26 | TD Cowen | MAINTAINED | Hold | Hold |
| Jul 14, 26 | Truist Securities | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate$9.28 / yr
Forward yield2.45%
5-year avg yield1.54%
Payout ratio57.56%
Ex-dividend dateSep 14, 2026
Next pay dateSep 22, 2026
Last split2:1
Split dateMay 31, 2005
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-08
Periodic Financial Reports
10-Q · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-07-16
Annual report of employee stock purchase
11-K · 2026-06-11
Corporate Changes & Voting Matters
8-K · 2026-06-05
Proxy Statements
DEFA14A · 2026-05-15
Corporate Changes & Voting Matters
8-K · 2026-05-11
Periodic Financial Reports
10-Q · 2026-05-05
Headlines
UnitedHealth Q3 Coming Up: Two Questions Investors Can't Ignore
Zacks · 9h ago
Ensign Builds More Scale as Financial Flexibility Remains Strong
Zacks · 10h ago
Centene Narrows Medicare Advantage Footprint as Costs Remain Elevated
Zacks · 11h ago
CVS' Health Care Benefits Arm Shows Better Core Trends: What's Ahead?
Zacks · 13h ago
Is UnitedHealth (UNH) a Good or Bad Investment at Today’s Price?
Insider Monkey · 18h ago
Coca Cola Stock And 2 Defensive Dividend Names Investors Are Watching
Simply Wall St. · 1d ago
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires · 1d ago
Elizabeth Warren, Josh Hawley Launch Probe Into Insurance Giants Over Claims That End With $0 Payouts — State Farm, Allstate Face Tough Questions: Report
Benzinga · 1d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.